Deanol in minimal brain dysfunction.
The literature on minimal brain dysfunction is confused, confusing and controversial. The statements that the condition exists, needs treatment, and that treatment may be pharmacological, are more expressions of faith than accepted fact. We believe they are true (within limits not discussed in the article). Furthermore, there is evidence that some patients with MBD are hypo-aroused, while others are not. The role of deanol in the treatment of MBD is still unclear, because of the complexities of identifying appropriate patients in terms of levels of arousal, as well as identifying appropriate measures of response. There is sufficient support for an effect of deanol in the literature to justify further investigation. Further studies should attend to important methodological problems as discussed.
D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000503:physiopathology; D002648:Child; D002675:Child, Preschool; D003265:Contingent Negative Variation; D003642:Deanol / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D004569:Electroencephalography; D004983:Ethanolamines / Q000627:therapeutic use*; D006801:Humans; D008959:Models, Neurological; D008960:Models, Psychological; D012107:Research Design; D013577:Syndrome
D004983:Ethanolamines; D003642:Deanol